Risedronate - Shiner Pharm
Alternative Names: Reosteo; Zhuo Rui boneLatest Information Update: 31 Oct 2021
Price :
$50 *
At a glance
- Originator Pharmascience
- Developer Shiner Pharm Corp
- Class Bisphosphonates; Calcium regulators; Osteoporosis therapies; Small molecules
- Mechanism of Action Bone resorption factor inhibitors; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Male osteoporosis; Postmenopausal osteoporosis
Most Recent Events
- 03 Jul 2019 Chemical structure information added
- 30 Nov 2012 Taiwan FDA approves risedronate for the treatment of Male and Postmenopausal osteoporosis in Taiwan (Shiner Pharm webite, February 2016)
- 30 Nov 2012 Launched for Male osteoporosis in Taiwan (PO) after November 2012